Trevi Therapeutics, Inc. (NASDAQ:TRVI) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 4:05 PM EDT
Company Participants
Jennifer Good – Co-Founder, CEO, President, Interim Principal Financial Officer & Director
Farrell Simon – Chief Commercial Officer
Conference Call Participants
Judah Frommer – Morgan Stanley, Research Division
Presentation
Judah Frommer
Equity Analyst
Welcome to this session of the Morgan Stanley Global Healthcare Conference. I’m excited to welcome the team from Trevi.
Before I do that, let me read a quick disclosure statement. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
So with that, Jennifer, Farrell, thank you for being here.
Question-and-Answer Session
Judah Frommer
Morgan Stanley, Research Division
Maybe we could just start with an overview of the company for those who might be less familiar, or newer to the story? That would be great.
Jennifer Good
Co-Founder, CEO, President, Interim Principal Financial Officer & Director
Yes, happy to do that. And thank you to everyone that came. I see some old friends in the audience. And Judah, thank you to you and Morgan Stanley, our newest relationship, newest analyst. That’s great.
So Trevi has had a strong year. We are a single-asset company. We have a drug that’s broadly in the opioid category but is in a subcategory of mixed agonist-antagonist. We’ll probably talk more about that. What’s interesting about it is you get the benefits of opioids, good efficacy, good safety without the addiction potential. So the drug has been around. It’s been unscheduled. So we can get more into that later.
But what’s unique about that mechanism is it works both centrally and peripherally. So I’m one of the two cofounders of the company. I co-founded it with the neurologist. Tom, my
Credit: Source link
